title: A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response.
authors.affiliation: US Oncology Research, Inc, The Woodlands, TX, USA. robert.rifkin@usoncology.com
authors.forename: Robert M
authors.initials: RM
authors.lastname: Rifkin
authors.forename: Andrew
authors.initials: A
authors.lastname: Greenspan
authors.forename: John F
authors.initials: JF
authors.lastname: Schwerkoske
authors.forename: Romeo A
authors.initials: RA
authors.lastname: Mandanas
authors.forename: Joe J
authors.initials: JJ
authors.lastname: Stephenson
authors.forename: George T
authors.initials: GT
authors.lastname: Kannarkat
authors.forename: Feng
authors.initials: F
authors.lastname: Zhan
authors.forename: Kristi A
authors.initials: KA
authors.lastname: Boehm
authors.forename: Lina
authors.initials: L
authors.lastname: Asmar
authors.forename: Roy
authors.initials: R
authors.lastname: Beveridge